The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Bone Marker and Bone Density Responses to Dopamine Agonist Therapy in Hyperprolactinemic Males
Abstract
The aim of this prospective study was to evaluate the bone mineral density (BMD) at lumbar spine and femoral neck levels and biochemical parameters of bone turnover in 20 consecutive hyperprolactinemic males before and after an 18-month treatment with different dopamine agonists. Six patients received bromocriptine at a dose of 2.5-10 mg/day; 7 patients received quinagolide at a dose of 0.075-0.3 mg/day; 7 patients received cabergoline at a dose of 0.5-1.5 mg/week. BMD, serum PRL, testosterone, dihydrotestosterone, and osteocalcin (OC), and urinary cross-linked N-telopeptides of type I collagen (Ntx) levels were measured before and every 6 months during treatment. At study entry, BMD values were lower in patients than controls at both lumbar spine (0.82 +/- 0.03 vs. 1.18 +/- 0.01 g/cm2; P < 0.001) and femoral neck (0.85 +/- 0.02 vs. 0.92 +/- 0.02 g/cm2; P < 0.05) levels. Osteopenia or osteoporosis was diagnosed in 16 patients at the lumbar spine and in 6 of them at the femoral neck level. A significant inverse correlation was found between lumbar spine and femoral neck BMD values and both PRL levels and disease duration (P < 0.01). In the 20 patients, serum OC levels were significantly lower (2.1 +/- 0.1 vs. 9.3 +/- 2.4 microg/L; P < 0.01), whereas Ntx levels were significantly higher (157.8 +/- 1.1 vs. 96.4 +/- 7.4 nmol bone collagen equivalent/mmol creatinine; P < 0.001) than control values. A significant inverse correlation was found between serum PRL and OC (P < 0.01), bu…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients who developed hyperprolactinemia in childhood or adolescence have more severe bone impairment than subjects who developed hyperprolactinemia in adulthood [20, 22].”
From Pituitary Disorders and Osteoporosis (2015) · cites this paper as [20]
In the citing paper
“A significant negative correlation was found between lumbar spine and femoral neck BMD values and both prolactin (PRL) levels and disease duration, which suggests that the duration of the disease is strongly correlated with the severity of bone loss [20, 22].”
From Pituitary Disorders and Osteoporosis (2015) · cites this paper as [20]
In the citing paper
“In one study, in all patients, osteocalcin (OC) levels were significantly lower and urinary cross-linked N-telopeptide of type I collagen (Ntx) levels were significantly higher; however BMD values were in normal ranges in 20% of the patients [20].”
From Pituitary Disorders and Osteoporosis (2015) · cites this paper as [20]
In the citing paper
“Dopamine agonist therapy restores gonadal function and increases vertebral BMD in most hyperprolactinemic women [19, 20].”
From Pituitary Disorders and Osteoporosis (2015) · cites this paper as [20]
In the citing paper
“A study on hyperprolactinemic males showed low BMD at the lumbar spine in 80% of patients, whereas only 30% subjects had a reduced BMD at the femoral neck. Similar finding was reported in women [20].”
From Pituitary Disorders and Osteoporosis (2015) · cites this paper as [20]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Long-term fracture prediction by bone mineral assessed at different skeletal sites
Dr. Melton, L. J., Atkinson, E. J., O'Fallon, W. M., Wahner, H. W., & Riggs, B. L. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650081010 · Cited by 862
Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791
Risk factors for spinal osteoporosis in men
Seeman, E., Melton, L. J., O'Fallon, W. M., & Riggs, B. L. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90878-1 · Cited by 659
Baseline Measurement of Bone Mass Predicts Fracture in White Women
Hui, S. L., Slemenda, C. W., & Johnston, C. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-5-355 · Cited by 580
ŠTĚPÁN, J. J., LACHMAN, M., ZVĚŘINA, J., PACOVSKÝ, V., & BAYLINK, D. J. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-523 · Cited by 424
Decreased spinal mineral content in amenorrheic women
Cann, C. E. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340290040017 · Cited by 409
Long-term Treatment of Galactorrhoea and Hypogonadism with Bromocriptine
Thorner, M. O., McNeilly, A. S., Hagan, C., & Besser, G. M. (1974) · BMJ · doi:10.1136/bmj.2.5916.419 · Cited by 406
Decreased Bone Density in Hyperprolactinemic Women
Klibanski, A., Neer, R. M., Beitins, I. Z., Ridgway, E. C., Zervas, N. T., & McArthur, J. W. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012253032605 · Cited by 360
Prediction of postmenopausal fracture risk with use of bone mineral measurements
Wasnich, R. D., Ross, P. D., Heilbrun, L. K., & Vogel, J. M. (1985) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(85)90338-2 · Cited by 329
Wang, C. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.10.3654 · Cited by 261
Cited by
Secondary Causes of Osteoporosis
FITZPATRICK, L. A. (2002) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)62214-3 · Cited by 311
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Colao, A., Vitale, G., Cappabianca, P., Briganti, F., Ciccarelli, A., De Rosa, M., Zarrilli, S., & Lombardi, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030979 · Cited by 256
Mazziotti, G., Frara, S., & Giustina, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00005 · Cited by 181
Vertebral fractures in males with prolactinoma
Mazziotti, G., Porcelli, T., Mormando, M., De Menis, E., Bianchi, A., Mejia, C., Mancini, T., De Marinis, L., & Giustina, A. (2011) · Endocrine · doi:10.1007/s12020-011-9462-5 · Cited by 109
Metadata
- Authors
- Di Somma, C.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1998-03-01
- Volume
- 83
- Issue
- 3
- Pages
- 807-813
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2164331064
- Cited by
- 117
- References
- 29
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 1 · 2022: 7 · 2021: 8 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 5 · 2016: 2 · 2015: 2 · 2014: 4 · 2012: 6
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- hyperprolactinemia, dopamine agonist therapy, bone mineral density, bone turnover markers, bromocriptine, quinagolide, cabergoline, osteopenia, osteoporosis, prolactin, osteocalcin, N-terminal telopeptide of type I collagen, testosterone, gonadal function, male patients, lumbar spine, femoral neck, disease duration
- MeSH terms
- Cabergoline, Adult, Aminoquinolines, Bone and Bones, Bone Diseases, Metabolic, Bromocriptine, Ergolines, Humans, Hyperprolactinemia, Male, Middle Aged, Prospective Studies, Biomarkers, Bone Density, Bone Remodeling, Dopamine Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bone Marker and Bone Density Responses to Dopamine Agonist Therapy in Hyperprolactinemic Males. https://app.cochat.ai/papers/10.1210/jc.83.3.807
- The paper
- Di Somma, C. (1998). Bone Marker and Bone Density Responses to Dopamine Agonist Therapy in Hyperprolactinemic Males. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.83.3.807
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
